Curated News
By: NewsRamp Editorial Staff
November 16, 2026
Helus Pharma's Phase 3 MDD Trial Hits Primary Endpoint
TLDR
- Helus Pharma's HLP003 achieved a 7.6-point MADRS advantage over placebo in Phase 3, positioning it as a potential first-in-class deuterated psilocin for major depressive disorder.
- The APPROACH trial randomized 222 adults to HLP003 or placebo, showing a 19.5-point MADRS reduction at week 6 versus 11.9 for placebo, with effects seen by day 2.
- Helus Pharma's HLP003 could offer a faster, more effective treatment for major depressive disorder, with 50.9% of participants achieving remission at week 6 versus 18.2% on placebo.
- HLP003 is a deuterated psilocin that acts on serotonin pathways to promote neuroplasticity, and it received FDA Breakthrough Therapy Designation for major depressive disorder.
Impact - Why it Matters
The positive Phase 3 results for HLP003 represent a significant milestone in the treatment of major depressive disorder, a condition that affects millions worldwide and often resists conventional therapies. With a 7.6-point placebo-adjusted improvement on the MADRS and a 50.9% remission rate at Week 6, HLP003 could offer a rapid and durable new option for patients who have not responded to existing treatments. The Breakthrough Therapy Designation from the FDA underscores the urgent need for innovation in mental health care. If subsequent trials confirm these findings, HLP003 could reshape the depression treatment landscape, providing hope for improved quality of life and reduced burden on healthcare systems. Investors and patients alike should watch Helus Pharma's progress closely as it advances toward regulatory submission.
Summary
Helus Pharma(TM) (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., has announced positive topline results from its pivotal Phase 3 APPROACH trial of HLP003 (deuterated psilocin) as an adjunctive treatment for adults with major depressive disorder (MDD). The randomized, double-blind, placebo-controlled study enrolled 222 participants and met its primary endpoint, showing a 19.5-point reduction from baseline on the Montgomery-Asberg Depression Rating Scale (MADRS) at six weeks for HLP003 compared to 11.9 points for placebo—a statistically significant 7.6-point difference (p<0.0001). Improvements were observed as early as Day 2 and maintained through Week 12, with a placebo-adjusted difference of 7.0 points (p<0.0001).
HLP003 also demonstrated significant improvements in response and remission rates, with 50.9% of treated participants achieving remission at Week 6 versus 18.2% on placebo. The treatment was generally well tolerated, with most adverse events mild to moderate and transient, though three treatment-related serious adverse events were reported. No new safety signals were identified. The APPROACH trial is the first of three studies in the company’s PARADIGM Phase 3 program, which also includes the ongoing EMBRACE pivotal trial and EXTEND long-term extension study. Helus Pharma expects to report topline results from EMBRACE in the fourth quarter of 2027 as it advances HLP003 toward potential regulatory approval and commercialization. For more details, visit the full press release at https://ibn.fm/IloYS.
Helus Pharma, founded in 2019, is a clinical-stage pharmaceutical company committed to helping minds heal by developing proprietary novel serotonergic agonists (NSAs)—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company’s NSAs aim to address the large unmet need for people suffering from depression, anxiety, and other mental health conditions. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the adjunctive treatment of MDD, and the company is also developing HLP004 in Phase 2 for generalized anxiety disorder. Helus Pharma operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Helus Pharma's Phase 3 MDD Trial Hits Primary Endpoint
